Renal donors with prostate cancer, no longer a reason to decline

Dholakia, Shamik; Johns, Richard L; Muirhead, Laura J.; Papalois, Vassilios; Crane, Jeremy

doi:10.1016/j.trre.2015.06.001

Cited by 7 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 The authors also appropriately conclude that the diagnosis of prostate cancer does not automatically disqualify a potential organ donor, again in keeping with current thought. 5 Remarkably, however, the series includes only the second reported case of prostate cancer transmission.…”

Section: Donor Cancer Transmission: Focusing On the Evidencementioning

confidence: 99%

Donor Cancer Transmission: Focusing on the Evidence

Nalesnik

2022

Transplantation

View full text Add to dashboard Cite

Section: Donor Cancer Transmission: Focusing On the Evidencementioning

confidence: 99%

Donor Cancer Transmission: Focusing on the Evidence

Nalesnik

2022

Transplantation

View full text Add to dashboard Cite

“…It is believed that kidney transplantation is now a gold standard treatment for ESRD (15). Kidney transplantation recipients have shown higher incidence rates of malignancies in recent decades because of increasing survival rates of these patients (16,17).…”

Section: Renal Transplantation and Kidney Cancersmentioning

confidence: 99%

Impact of cancers on the kidney function and structure; an ignored entity

Davoodi¹,

Bahadoram²,

Bahadoram³

et al. 2018

J Renal Inj Prev

View full text Add to dashboard Cite

Important declines have been observed in urological cancer-related mortality in recent decades, mainly due to improvements in treatments of prostate cancer, less exposure to tobacco smoking as well as occupational carcinogens of kidney and bladder. However, because of global population ageing, age-related urinary tract cancers are expected to increase in the near future despite improved primary prevention, early detection and more efficient treatment. In this article, renal cell carcinoma (RCC), kidney transplantation, cancer and acute kidney injury (AKI), lung cancer and chronic kidney disease (CKD), breast cancer, prostate cancer, cervix cancer and brain cancer and their associations with kidney function and structure have been discussed. In conclusion, kidney and cancers have interaction with each other. Kidney carcinoma can be metastasizing to other organs as well as other cancer to kidney. Therefore, it is recommended to consider the potential effect of kidney functions and interaction with other cancers in each malignancy.

show abstract

“…A recent study from Dholakia et al examined existing literature, looking for insight into kidney transplantation from donors with prostate cancer (with an estimated donor incidence of 3-18.5%). 60 With more than 100 kidney transplants in the literature from patients with known prostate cancer, there have been no incidences of transmission. However, the risk of cancer transmission will never be zero, with a case report 61 demonstrating prostate cancer transmission following orthotopic heart transplantation from a donor with node positive disease.…”

Section: Donor Prostate Cancermentioning

confidence: 99%

Donation after Brain Death versus Donation after Circulatory Death: Lung Donor Management Issues

Snell

Levvey

Levin

et al. 2018

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Lung transplantation (LTx) has traditionally been limited by a lack of suitable donor lungs. With the recognition that lungs are more robust than initially thought, the size of the donor pool of available lungs has increased dramatically in the past decade. Donation after brain death (DBD) and donation after circulatory death (DCD) lungs, both ideal and extended are now routinely utilized. DBD lungs can be damaged. There are important differences in the public's understanding, legal and consent processes, intensive care unit strategies, lung pathophysiology, logistics, and potential-to-actual donor conversion rates between DBD and DCD. Notwithstanding, the short- and long-term outcomes of LTx from any of these DBD versus DCD donor scenarios are now similar, robust, and continue to improve. Large audits suggest there remains a large untapped pool of DCD (but not DBD) lungs that may yet further dramatically increase lung transplant numbers. Donor scoring systems that might predict the donor conversion rates and lung quality, the role of ex vivo lung perfusion as an assessment and lung resuscitation tool, as well as the potential of donor lung quality biomarkers all have immense promise for the clinical field.

show abstract

Renal donors with prostate cancer, no longer a reason to decline

Cited by 7 publications

References 29 publications

Donor Cancer Transmission: Focusing on the Evidence

Donor Cancer Transmission: Focusing on the Evidence

Impact of cancers on the kidney function and structure; an ignored entity

Donation after Brain Death versus Donation after Circulatory Death: Lung Donor Management Issues

Contact Info

Product

Resources

About